Dosimetry Based PRRT Versus Standard Dose PRRT With Lu-177-DOTATOC in NEN Patients

PHASE2RecruitingINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

February 1, 2020

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions

Neuroendocrine Neoplasm

Interventions

DRUG

Lu-177-DOTA-Octreotide

Lu-177-DOTATOC in standard doses or individualized doses.

Trial Locations (1)

RECRUITING

Aarhus University Hospital, department of Nuclear medicine and PET centre, Aarhus

All Listed Sponsors

lead

Tine Gregersen, MD

OTHER